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Abstract
Ongoing clinical trials are evaluating the benefits of systemic blockade of lymphocyte activation 
gene-3 (LAG-3) signals to improve immunity to tumors. Those studies are founded on the well-
established inhibitory role of LAG-3 in regulating CD8+ T cells during chronic virus infection and 
anti-tumor responses. However, the T cell response in LAG-3 deficient mice is similar in size and 
function to that in wild type animals, suggesting LAG-3 has nuanced immune-regulatory 
functions. We performed a series of adoptive transfer experiments in mice to better understand the 
T cell-intrinsic functions of LAG-3 in the regulation of CD8+ T cell responses. Our results 
indicate that LAG-3 expression by CD8+ T cells inhibits their competitive fitness and results in a 
slightly reduced rate of cell division in comparison to LAG-3 deficient cells. This cell-intrinsic 
effect of LAG-3 was consistent across both acute and chronic virus infections. These data show 
that LAG-3 directly modulates the size of the T cell response and support the use of LAG-3 
blockade regimens to enhance CD8+ T cell responses.
Introduction
Chronic virus infections are a major health issue worldwide, with millions of people 
currently living with diseases caused by viruses such as HIV, HCV, and HBV. During these 
infections, T cell responses become functionally inactive through a process known as T cell 
exhaustion and fail to clear the infection (1). Exhausted CD8+ T cells show diminished 
cytokine production, weakened cytolytic activity, and lower antigen-induced proliferation in 
large part due to their co-expression of a series of surface inhibitory receptors, including 
programmed cell death protein 1 (PD-1), lymphocyte activation gene-3 (LAG-3, CD223), 
2B4 (CD244), CD160, and T cell immunoglobulin mucin-3 (Tim-3) (2). Recent data in 
mouse models indicates that T cell dysfunction can be reversed by combined antibody 
blockade of these receptors, especially PD-1 and LAG-3, leading to improved clearance of 
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viral and bacterial pathogens (3, 4). Similar results have also been seen following blockade 
of LAG-3 in tumor models, resulting in the elimination of tumors (5–7). Therefore, it is 
important to understand the specific effects of LAG-3 on CD8+ T cells to improve vaccines 
and the treatment of persistent infections and tumors.
LAG-3 is a surface receptor expressed by activated CD8+ T cells that binds to MHC-II with 
a higher affinity than the T cell co-receptor CD4 (8–11). LAG-3 associates with the TCR at 
the immunological synapse following TCR stimulation and inhibits signaling (12, 13). 
During an acute infection LAG-3 is expressed early upon activation, perhaps due to its rapid 
translocation to the surface from a recycling endosomal compartment (14). Surface 
expression of LAG-3 can be efficiently reduced by two transmembrane metalloproteases that 
cleave LAG-3 from the cell surface (2, 15). Early studies highlighted the ability of LAG-3 to 
act as an inhibitory receptor for CD8+ T cell expansion and homeostasis (16, 17). Further 
studies showed that surface LAG-3 expression is maintained for an extended period of time 
during persistent virus infections, typically for as long as the antigen is present (2). The 
inhibitory function of LAG-3 was confirmed by antibody blockade studies in which LAG-3 
interference led to enhanced T cell responses and improved virus clearance (3). However, in 
some circumstances the absence of LAG-3 appears to have no effect on either T cell 
expansion or clearance of a persistent virus infection (18).
The discrepancies between these results could be partially due to the expression of LAG-3 
by other cell types. Activated CD4+ T cells express LAG-3, which negatively regulates 
CD4+ T cell responses and homeostatic proliferation (16, 17, 19). CD4+ regulatory T cells 
(Treg) also express LAG-3 and lose functionality in the absence of LAG-3 (20). LAG-3 
deficiency leads to altered homeostatic regulation of plasmacytoid dendritic cells (pDC), a 
key cell type in the production of type I interferon (21, 22). NK cells express LAG-3, and 
LAG-3 deficient mice have reduced NK cell activity (11, 23). There has also been a report 
documenting LAG-3 expression on B cells (24), though the functional significance of 
LAG-3 in B cell responses is not known. Thus, many cell types express LAG-3 and any or 
all of these cells could impact CD8+ T cell responses. Because of this, the interpretation of 
data involving systemic antibody-mediated blockade of LAG-3 must also take into account 
other LAG-3+ targets and their regulatory effects.
Herein, we addressed the cell-intrinsic role for LAG-3 expression on CD8+ T cell responses 
following acute and chronic virus infection. We found that LAG-3 expression by CD8+ T 
cells decreases the size of the virus-specific CD8+ T cell response without inducing 
functional changes. We used competition experiments to reveal that LAG-3 deficient T cells 
outcompeted their LAG-3 sufficient counterparts. Thus, LAG-3 has a cell-intrinsic negative 
effect on CD8+ T cell responses that results in reduced fitness.
Materials and Methods
Mice and Virus
C57BL/6 mice were purchased from Jackson ImmunoResearch Laboratory. LAG-3−/− mice 
were originally generated by Drs. Diane Mathis and Christophe Benoist at the Institut 
Génétique Biologie Moléculaire Cellulaire (Illkirch-Graffenstaden, France) and 
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subsequently backcrossed to C57BL/6 by Dr. Dario Vignali at St. Jude Children's Research 
Hospital (Memphis, TN, USA) and are a gift from Dr Vignali and St. Jude Children's 
Hospital (16, 23, 25). P14 TCR-transgenic mice that have T cells specific for the LCMV 
epitope GP33–41 were crossed to C57BL/6.Thy1.1 or C57BL/6.Ly5a mice to generate P14 
Thy1.1+ and P14 Ly5a+ mice. The P14 Ly5a+ mice were crossed to LAG-3−/− mice to 
generate the P14 LAG-3 deficient TCR-transgenic mice. Armstrong and Clone13 strains of 
LCMV were prepared and quantitated as described previously (26). Mice were infected by 
intravenous administration of 2 × 106 plaque forming units of Clone13 or intraperitoneal 
administration of 2 × 105 plaque forming units of Armstrong. Infectious LCMV in serum, 
liver, lung, and kidney was quantified by plaque assay on Vero cell monolayers (26). All 
mouse experiments were approved by the University of North Carolina-Chapel Hill 
Institutional Animal Care and Use Committee. Mice were sacrificed by cervical dislocation 
after anesthetization with isoflurane.
Flow cytometry
Spleen cells were stained directly ex vivo with antibodies against CD8 (53–6.7), CD44 
(IM7), CD62L (MEL-14), CD127 (LG.3A10), CD160 (7H1), CD244 (m2B4(B6)458.1), 
KLRG-1 (2F1/KLRG1), Ly5a (A20), LAG-3 (C97BW), PD-1 (RMP1-30), and Thy1.1 
(eBioscience, HIS5.1). Cells were stained for intracellular Ki-67 (16A8), Bcl2 (3F11, BD 
Biosciences), and Bim (C34C5, Cell Signaling Technology) following fixation and 
permeabilization using buffers from Biolegend. Cytokine production was assessed by the 
intracellular cytokine staining (ICS) assay as described previously (27). In brief, splenocytes 
were stimulated ex vivo with LCMV peptide GP33-41 for 5-6 hours in the presence of 
brefeldin A, followed by surface staining, fixation, permeabilization, and staining for IFN-γ 
(XMG1.2), TNF-α (MP6-XT22), IL-2 (JES6-5H4). All antibodies were from Biolegend, 
except where indicated. Tetramer staining was done using strepavidin-APC-labeled 
tetrameric-complexes of Db complexed with LCMVGP33-41 peptide; the tetramers were 
produced from the NIH core facility. Cell staining was analyzed by four-color flow 
cytometry using a BD Biosciences FACSCALIBUR and analyzed by FlowJo software 
(www.treestar.com).
Adoptive transfers
Spleen cells were isolated from WT or LAG-3 deficient P14 mice and the frequency of 
CD8+ T cells was determined by flow cytometry. The spleen cells were injected directly into 
WT or LAG-3 deficient mice via tail vein injection; in the dual adoptive transfer experiments 
the WT and LAG-3−/− spleen cells were mixed to contain equivalent numbers of CD8+ T 
cells prior to injection. The cells were allowed to engraft for 4 days before the recipient mice 
were infected. The donor cell populations were identified due to their differing expression of 
the Thy1.1, Thy1.2, Ly5a, or Ly5b antigens, as indicated.
Statistics
Statistical analyses were performed using Prism software (www.graphpad.com), employing 
an unpaired two-tailed Student's t-test to evaluate the significance of differences between 
groups.
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Results
Antiviral CD8+ T cell responses are normal in LAG-3 deficient mice
LAG-3 is a T cell activation marker whose prolonged expression on virus-specific CD8+ T 
cells during chronic infection identifies cells that are functionally exhausted (2). There is 
significant interest in LAG-3 because antibody-mediated blockade of LAG-3, particularly in 
combination with PD-1 blockade, restores functionality to exhausted T cells in models of 
chronic infection and cancer therapy (3–7). However, multiple reports have seen little effect 
on antiviral T cell responses in mice deficient for LAG-3, implying that the functional 
consequences of LAG-3 are limited in time or context (18, 23). To better understand the role 
of LAG3 in T cell responses, we quantified the expression of LAG-3 on LCMV-specific 
tetramer+ CD8 T cells in response to different variants of LCMV that result in acute 
(Armstrong) or persistent (Clone13) infection. LAG-3 was induced to high levels at day 5 
with both strains. The percentage of LAG-3 expressing T cells returned to baseline by day 8 
for Armstrong (Fig. 1A), however, following Clone13 infection, LAG-3 expression was 
maintained for at least 60 days on a population of LCMV-specific CD8+ T cells (Fig. 1A). 
The surface level of LAG-3 closely tracked with the amount of virus in the animals, 
consistent with previous studies (2). LAG-3 is typically regarded as a negative regulator of T 
cell responses, but multiple cell types can express LAG-3, including CD4+ and CD8+ T 
cells, Tregs, B cells, pDCs, and NK cells (11, 20, 21, 24). LAG-3 was induced on NK cells 
and dendritic cells early after LCMV-Armstrong infection, though expression on B cells was 
undetectable (Fig. 1B); LAG-3 expression on non-T cells (i.e., cells lacking CD4 & CD8) 
was transient, as we could not detect it during the memory phase (data not shown).
To evaluate the function of LAG-3, we measured antiviral T cell responses following LCMV 
infection of C57BL/6 (WT) and LAG-3 deficient (LAG3−/−) mice. In response to Armstrong 
infection, WT and LAG-3 deficient mice had a massive expansion of CD8+ T cells, with 
equivalent numbers of double positive IFN-γ / TNF-α producing cells at the peak of the 
primary response (day 8) (Fig. 2A). Furthermore, infectious virus was undetectable in WT 
and LAG-3 deficient mice, indicating efficient CTL-mediated viral clearance of the acute 
infection (data not shown). There was also no defect in the formation of memory CD8+ T 
cells, as at day 80 there was no difference in the number of LCMV-specific cytokine 
producing cells (Fig. 2A).
In response to Clone13 infection, the CD8+ T cell responses at early (day 8) and late (day 
60) time points were predictably reduced compared to Armstrong; however, the numbers of 
LCMV-specific cytokine-producing T cells were equivalent between WT and LAG-3 
deficient mice (Fig. 2B). Tetramer staining also revealed equivalent numbers of virus-
specific T cells in WT and LAG-3 deficient mice (Fig. 2C). Consistent with the equivalent T 
cell responses, there was no difference between LAG-3 sufficient and LAG-3 deficient mice 
in the amount of virus detected over time in the blood and at day 60 in various tissues (Fig. 
2D). These data indicate that the complete loss of LAG-3 does not impact antiviral T cell 
responses and clearance of acute or chronic infections, confirming previous studies (18).
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T cell-intrinsic LAG-3 expression inhibits the accumulation and maintenance of CD8+ T 
cells
We considered that LAG-3 could affect T cell responses through direct or indirect 
mechanisms. To determine if there is a negative role for LAG-3 that is intrinsic to CD8+ T 
cells, we crossed the LCMVGP33-41-specific TCR-transgenic P14 mice onto the LAG-3 
knockout background to generate LAG-3 deficient CD8+ T cells that specifically recognize 
LCMV. These LAG-3−/− P14 cells were adoptively transferred in conjunction with equal 
numbers of WT P14 cells into congenic WT mice prior to Armstrong infection (Fig. 3, A & 
B). This dual-adoptive transfer approach allows us to directly compare responses between 
WT and LAG-3−/− T cells within identical inflammatory environments. In uninfected mice 
there was a 1:1 ratio between the two cell types, signifying that there was no difference in 
engraftment or homeostatic proliferation (Supplemental Fig. S1A–C). Additionally, there 
was no difference in the in vitro proliferative ability of the WT and LAG-3 deficient P14 
cells to GP33-41 peptide (Supplemental Fig. S1D). At day 8 post infection there was a 
massive expansion of both WT and LAG-3−/− T cells with little difference in the WT:KO 
ratio or the total number of each population (Fig. 3, C and D). However, by day 15 there was 
an increase in the frequency and total number of LAG-3 deficient P14 cells (Fig. 3C). The 
difference between WT and LAG-3−/− P14 cells that was observed in the blood as early as 
day 15 was maintained in the spleen through day 45 (Fig. 3D). These data show that the 
primary expansion of CD8+ T cells during an acute infection is independent of LAG-3, but 
the formation or maintenance of memory cells is inhibited by LAG-3 in a cell-intrinsic 
manner.
To determine the functional consequences of the absence of LAG-3 on CD8+ T cells, we 
measured cytokine production by the WT and LAG-3−/− P14 cells at day 8 and 45 post 
infection. At day 8 equal percentages of WT and LAG-3−/− cells produced IFN-γ, TNF-α, 
and IL-2, resulting in equivalent numbers of cytokine-positive cells (Fig. 3E). There was 
also no difference in the percentage of cells making each cytokine at day 45, but the total 
number of LAG-3−/− cytokine-positive cells was increased because there were more 
LAG-3−/− cells in these animals (Fig. 3F). Taken together, these data indicate that LAG-3 
reduces the total number of memory CD8+ T cells but does not perturb memory cell 
expression of cytokines.
Because T cell expression of LAG-3 led to fewer memory cells, we considered that LAG-3 
might affect memory precursor cells that develop early during an acute infection. CD8+ T 
cells can be divided into memory-precursor effector cell (MPEC) and short-lived effector 
cell (SLEC) subsets (28, 29). These subsets are distinguished by their expression of KLRG-1 
and IL7Ra. At day 8, a majority of the WT and LAG-3 knockout P14 cells expressed 
KLRG-1 and not IL-7Ra (SLEC), while at day 45 similar proportions of cells expressed 
IL-7Ra and KLRG-1 (MPEC) (Supplemental Fig. S2). The cells uniformly expressed the 
activation marker CD44 at both time points, while CD62L was higher at day 45 compared to 
day 8 (Supplemental Fig. S2). Interestingly, the frequencies of P14 cells expressing these 
markers were not changed by the absence of LAG-3 (Supplemental Fig. S2). These data 
suggest that LAG-3 on T cells does not shift the differentiation of CD8+ T cells towards the 
MPEC subset.
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Since transient LAG-3 expression after acute infection had long-term negative effects on the 
number of memory CD8+ T cells, we next assessed whether sustained LAG-3 expression 
during persistent infection would reduce T cell responses (2). We followed the same 
procedure as above by adoptively transferring congenically marked WT and LAG-3−/− P14 
cells into WT B6 recipient mice (Fig. 4, A and B). The frequency of each cell type was 
followed in the blood over time after infection with the Clone13 strain of LCMV. At day 7 
the WT and LAG-3−/− P14 cells were found at equivalent frequencies, indicating that the 
initial expansion is independent of LAG-3 expression (Fig. 4C). At later time-points the 
LAG-3 deficient cells were much more abundant than their WT counterparts in the blood 
(Fig. 4C). This culminated in a 5-fold increase in the number of LAG-3−/− splenic P14 cells 
at day 56 when compared to the number of WT cells (Fig. 4D). Therefore, intrinsic LAG-3 
signaling restricts the magnitude of the CD8+ T cell response during persistent and acute 
viral infections.
We measured the production of cytokines and surface expression of exhaustion and 
activation markers to determine if T cell function is altered by LAG-3 signaling. The 
frequency of P14 cells that produced IFN-γ, TNF-α, and IL-2 was equivalent between WT 
and LAG-3−/− cells, though the total numbers of LAG-3−/− cytokine-positive cells were 
higher than WT due to the increased number of virus-specific LAG-3−/− cells (Fig. 4E). 
None of the cell surface proteins that correlate with functional exhaustion (PD-1, 2B4, and 
CD160) or T cell activation (KLRG-1) were differentially expressed by WT and LAG-3 
knockout CD8+ T cells (Fig. 4F). Thus, the absence of LAG-3 on T cells results in more 
virus-specific CD8+ T cells but does not prevent CD8+ T cell exhaustion during 
disseminated infection.
LAG-3 deficient CD8+ T cells outcompete cells that express LAG-3
T cells compete for limited resources (antigen, cytokines, etc.) as they respond to infection 
(30, 31). We hypothesized that the LAG-3−/− P14 cells better competed for these resources 
than WT P14 cells and were better able to accumulate after infection. To address this 
possibility we performed the adoptive transfer approach with different numbers of 
transferred cells. At low cell transfer numbers there should be ample resources for all cells 
(limited competition), while increasing the number of transferred cells should limit the 
available resources and reveal whether LAG3−/− cells have a competitive advantage over WT 
cells. Thus, we co-transferred 102, 2×103, or 4×104 each of WT and LAG3−/− P14 cells to 
WT host mice and infected with Armstrong (Fig. 5A). At the lowest cell transfer dose, there 
was equivalent expansion of WT and LAG-3 deficient cells, with a 1:1 ratio between the two 
at day 16 (Fig. 5B). However, the LAG-3−/−:WT cell ratio increased to 4:1 at the medium 
cell dose and 8:1 at the highest transfer dose (Fig. 5B). Therefore, as the number of 
transferred cells increased, the competitive advantage of the LAG-3−/− P14 cells became 
more apparent. The difference between WT and LAG-3 deficient cells was not due to 
selective rejection of the WT cells, as we performed a similar experiment with two separate 
populations of congenically marked WT cells (Fig. 5C). As expected, the WT:WT cell ratio 
was 1:1 at all cell transfer doses, indicating that when there is no competitive advantage of 
one population over the other, the donor cells expand equivalently (Fig. 5C). In summary, 
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these data indicate that LAG-3 deficient CD8+ T cells are able to outcompete WT CD8+ T 
cells following acute infection.
To further explore the role of competition between WT and LAG-3−/− CD8+ T cells during 
antiviral immune responses, we adoptively transferred WT LCMVGP33-41-specific TCR-
transgenic P14 cells into WT or LAG-3−/− host mice (Fig. 6A). Thus, the same LAG-3 
sufficient CD8+ T cells are compared in mice that have competing populations of 
endogenous WT or LAG-3 deficient CD8+ T cells. Following Armstrong infection, the P14 
cells expanded equivalently in the WT and LAG-3 deficient hosts at day 8 (Fig. 6, B and C). 
In contrast, there was a significant decrease in the frequency of memory P14 cells in the 
LAG-3−/− mice at day 40 (Fig. 6, B and C). To determine the functional impact of 
competition with endogenous T cells, we measured cytokine production by the WT P14 
cells after their expansion in WT and LAG-3 deficient environments. The percentages of 
P14 CD8 T cells producing IFN-γ & TNF or IFN-γ & IL-2 were equivalent between the 
WT and LAG-3−/− hosts at day 8 and 40 (Fig. 6, D and E). However, there was a significant 
decrease in the overall number of cytokine-producing P14 cells at day 40 when the cells 
were in the LAG-3 deficient hosts (Fig. 6E). These data further show that WT CD8+ T cells 
are outcompeted by LAG-3 deficient T cells without changing the functional capacity of the 
cells.
Minor influence of LAG-3 on CD8+ T cell division and apoptosis
The competitive advantage of the LAG-3−/− T cell response is likely due to either enhanced 
proliferation or reduced apoptosis. The apoptosis of naïve and activated T cells is tightly 
regulated by proteins of the Bcl-2 superfamily (32–34). We measured the expression of the 
anti-apoptotic family member Bcl-2 and the pro-apoptotic family member Bim in WT and 
LAG-3 deficient P14 cells at day 7 and 13 post-infection. The level of Bim was significantly 
lower in the absence of LAG-3; this coincided with a slightly, but not statistically significant, 
lower level of Bcl-2 in LAG-3−/− CD8+ T cells (Fig. 7A). The ratio between Bim and Bcl-2 
can be used to evaluate whether T cells will likely undergo apoptosis (32). There was a trend 
towards a higher Bim:Bcl-2 ratio in the WT P14 cells, suggesting that WT cells are more 
prone to apoptosis than LAG-3−/− cells, but the difference in the ratio was not statistically 
significant (Fig. 7B).
For a functional readout of the effects of LAG-3 on T cell survival, we cultured WT and 
LAG-3−/− P14 cells ex vivo and stained for surface Annexin-V, which is indicative of cells 
undergoing apoptosis. On day 7 or 13 post-Armstrong or -Clone13 infection, WT and 
LAG-3−/− T cells showed no difference in Annexin-V binding (Fig. 7C). Additionally, the 
percentage of T cells expressing activated Caspase 3, a key protein in the apoptotic cascade, 
was not different for WT and LAG-3 deficient P14 cells during Clone13 infection (Fig. 7D). 
These data indicate that despite lower levels of the pro-apoptotic protein Bim, the increased 
expansion of LAG-3−/− CD8+ T cells does not appear to be due to enhanced survival.
Next we stained WT and LAG-3−/− P14 cells with Ki-67, which specifically detects dividing 
cells (35), to determine if LAG-3 signaling impacts cell division. Following Armstrong 
infection, 70–80% of P14 cells were Ki-67 positive at day 6 when there is replicating virus, 
but by day 13, when the virus was eliminated, the frequency of dividing cells declined to 
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~20% (Fig. 7E). In response to Clone13, 60–70% of WT and LAG-3−/− P14 cells 
proliferated at day 6 and 50% of them continued to divide at day 13 (Fig. 7E), likely due to 
the prolonged virus infection. In all cases, there was no difference in the frequency of Ki-67-
positive cells between the WT and LAG-3 deficient populations (Fig. 7E). These data 
indicate that the frequency of WT and LAG3−/− T cells that are within the cell cycle is not 
changed; however Ki-67 staining does not provide a sensitive analysis of how rapidly cells 
divide. To more definitively measure the rate of proliferation, we performed a cell transfer 
experiment using CFSE dilution as a measurement of cell division (Fig. 7F). WT and 
LAG-3−/− P14 cells were co-transferred to WT B6 mice and infected with Clone13. At day 
8 post-infection splenic CD8+ T cell were labeled with CFSE and re-transferred to new WT 
B6 mice that had been infected in parallel; CFSE dilution was measured 3 days later. There 
was a slightly higher frequency of divided LAG-3 deficient P14 cells compared to WT P14 
cells in the same host (Fig. 7G). In 5 of the 6 recipient mice there was a greater percentage 
of divided LAG3−/− CD8+ T cells in comparison to the WT cells. These data suggest that 
the LAG-3 deficient T cells have a slightly higher rate of proliferation than WT cells.
Discussion
The data presented here show that LAG-3 directly inhibits the accumulation but not function 
of virus-specific T cells following acute or chronic infections. We find that when LAG-3−/− 
CD8+ T cells are compared “side-to-side” with LAG3-sufficient T cells, the LAG-3 
deficient T cells outcompete WT T cells as they establish memory to acute infection. LAG-3 
deficient CD8+ T cells also are sustained at higher levels than WT T cells during chronic 
virus infection. Thus, LAG-3 regulates CD8+ T cell responses through a cell-intrinsic 
manner. Our data support a model wherein virus-specific T cell numbers are constrained by 
available resources (antigen, cytokines, etc.) and inhibited by LAG-3.
That LAG-3 reduces the abundance of virus-specific T cells after infection has not been 
noted before, most likely because LAG-3 deficient mice generate T cell responses that are 
equivalent to those in infected WT mice (Figure 2; 18). These findings have partly 
contributed to the perspective that reversal of T cell exhaustion should rely on simultaneous 
blockade of LAG-3 and PD-1. The competitive advantage of the LAG-3 deficient T cells is 
apparent only when WT and LAG-3−/− CD8+ T cells are compared in the same animals. 
Thus, when LAG-3 deficient mice are infected, T cells within that mouse compete 
vigorously against each other, yielding a response that is equivalent to that seen in LAG-3 
sufficient mice, whose T cells develop under less stringent conditions. The lack of additional 
inflammatory resources in the LAG-3 knockout mice prevents the T cell response in these 
animals from being any larger, regardless of the enhanced fitness of the T cells.
The data in Figure 6 show that WT memory is reduced when WT cells are in a LAG-3−/− 
recipient. We interpret this as being due to strong competition from endogenous LAG-3−/− 
CD8+ T cells in the recipients. Nevertheless, there are other possible explanations for a 
CD8+ T cell-extrinsic effect of LAG-3 that promotes T cell responses. Multiple cell types 
can express LAG-3, including pDCs, Tregs, and NK cells (Figure 1; 11, 20, (21, 22). For 
example, it could be that LAG-3 deficient Treg cells are more suppressive than those in WT 
mice, though previous studies in other models have shown that LAG-3 deficient Treg cells 
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have reduced suppressive activity (20). Another possibility is that cDCs, which we show in 
Figure 1 express low levels of LAG-3 in infected mice, could be important in this process. It 
is plausible that DC-intrinsic LAG-3 signaling improves APC function and T cell responses; 
thus, cDCs in LAG-3 deficient mice could be weaker at stimulating T cells. In addition to 
intrinsic LAG-3 signaling, cDCs also express MHC-II, which interacts with LAG-3. It has 
been noted that a LAG-3-Ig fusion protein enhances cDC activity by binding to MHC-II (15, 
36, 37), and surface-bound LAG-3 on human T cells activates cDCs in an in vitro culture 
system (38). IMP321, a soluble fusion protein consisting of LAG-3, has been evaluated for 
its ability to stimulate cDCs and improve T cell responses to several tumors. These studies 
raise the possibility that WT CD8+ T cells poorly establish memory in the absence of 
LAG-3 expression on non-CD8+ T cells.
Figure 1 shows that LAG-3 on T cells is dynamic and varies with infection. LAG-3 is 
transient during acute infection but sustained during chronic infection. Correspondingly, the 
LAG-3 KO memory T cells are roughly 2-fold increased over WT T cells after acute 
infection (Figure 3C–D) but 3-4-fold increased during chronic infection (Figure 4C–D). 
Thus the strength of the response is linked to the duration of LAG3-expression and 
inhibition of WT T cells. Interestingly, when LAG-3 is expressed, T cells show a distribution 
of expression with some cells LAG-3hi and others LAG-3lo. Given the direct inhibitory 
effect of LAG-3, it may be that the LAG-3lo T cells better survive to memory whereas the 
LAG-3hi T cells are selected out of memory, thus impacting immunodominance hierarchies. 
It is noteworthy that the expression of LAG-3 was brief following acute infection, yet the 
effect on T cell number manifested during the contraction phase and on into memory. This 
implies that early LAG-3 signaling during the expansion phase programs T cell contraction 
at a later time when LAG-3 expression has ceased. These data suggest that pharmacological 
compounds that interfere with this pathway early on, such as during vaccination, might 
improve vaccine-induced T cell memory.
As T cell numbers increase (and intraclonal competition becomes more severe), the 
advantage of not expressing LAG-3 for generating large populations of virus-specific T cells 
becomes more apparent (Figure 5A–B). We are unsure how LAG-3 deficiency improves the 
ability of T cells to establish greater numbers of memory cells. It could be that enhanced T 
cell competition for cytokines gives LAG-3−/− T cells an advantage, however, we did not 
detect differences in the expression levels of IL-2, IL-7, and IL-15 cytokine receptors 
(Supplemental Fig. S2 & data not shown) that promote memory T cell maintenance. Perhaps 
LAG-3-MHC-II interactions impact the movement of CD8+ T cells within lymphoid 
environments and affect their ability to access these cytokines without varying the 
expression level of the cytokine receptors.
We considered that LAG-3 signals affect either T cell apoptosis or proliferation. We found 
that direct LAG-3 signaling had no effect on Ki-67 staining and a marginal negative effect 
on CD8+ T cell proliferation (Fig. 7). These data are consistent with results showing that 
LAG-3 blockade during chronic LCMV infection enhances cell division (3). Additionally, 
one study used antibodies to cross-link LAG-3, and another study used metalloprotease 
inhibitors to prevent LAG-3 cleavage from cells; the resulting data were consistent with 
LAG-3 signals decreasing cellular proliferation (12, 15). We considered that LAG-3 may 
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promote T cell apoptosis. The expression level of the pro-apoptotic protein Bim was 
significantly higher in LAG-3-expressing T cells (Supplemental Figure S3). Though we did 
not identify changes in apoptosis after culturing the cells in vitro, the in vivo survival of T 
cells is likely subject to requirements that are not replicated in the in vitro experiments. The 
enhanced Bim levels in WT cells may reflect greater apoptosis in vivo. While the differences 
in apoptosis potential or cell proliferation appear minor, slight changes in cell division that 
are compounded across many cycles can exponentially increase overall responses.
Interference with LAG-3 and PD-1 improves tumor-infiltrating lymphocyte responses to 
tumors (6, 39). New clinical trials are evaluating the safety and efficacy of anti-LAG-3 to 
improve immune responses to chronic lymphocytic leukemia, Hodgkin lymphoma, non-
Hodgkin lymphoma, and solid tumors (NCT01968109; NCT02061761) (40). Our results 
show that LAG-3 expression by T cells restricts the competitive fitness of antigen-specific 
CD8+ T cells and directly reduces their number during acute and chronic virus infections. 
These data support the use of LAG-3 antibody-blockade as a method of enhancing T cell 
responses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
2Abbreviations
ICS intracellular cytokine staining
LAG-3 lymphocyte activation antigen-3
LCMV lymphocytic choriomeningitis virus
PFU plaque forming unit
pi post-infection
pDC plasmacytoid dendritic cell
Treg regulatory T cell
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Figure 1. LAG-3 expression on CD8+ T cells, NK cells, B cells, and dendritic cells
(A)WT B6 mice were infected with LCMV-Armstrong or LCMV-Clone13. The frequency of 
splenic LCMV-specific CD8+Db/GP33+ cells expressing LAG-3 at various times post-
infection is shown as mean +/− SEM, n=3–6 per group over 3 experiments. (B) WT B6 mice 
were infected with LCMV-Armstrong. The histograms depict LAG-3 expression on 
NK1.1+DX5+ NK cells, CD19+ B cells, and CD11c+CD3− dendritic cells in the spleen at 
day 3. One mouse, representative of 3, is shown for each.
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Figure 2. The complete absence of LAG-3 does not affect the number, function, or longevity of 
antiviral CD8+ T cell responses
T cell responses and viral loads were measured in WT or LAG-3−/− mice following acute or 
chronic infection. (A) WT B6 and LAG-3−/− mice were infected with LCMV-Armstrong and 
the total number of splenic IFN-γ/TNF-α double positive CD8+ T cells following ex vivo 
stimulation with various LCMV peptides was measured by intracellular cytokine staining at 
days 8 (left) and 80 (right) post-infection (pi). (B–D) WT B6 and LAG-3−/− mice were 
infected with LCMV-Clone 13. (B) The total number of splenic IFN-γ/TNF-α double 
positive CD8+ T cells following ex vivo stimulation with various LCMV peptides was 
measured by ICS at days 8 (left) and 60 (right) pi. (C) Examples of Db/GP33 tetramer 
staining of CD8+ T cells in the spleens of either WT or LAG-3−/− mice at day 60 (left); the 
numbers indicate the percentage of tetramer+ cells among CD8+ T cells. The total number 
of splenic LCMV-specific CD8+Db/GP33+ cells in either WT or LAG-3−/− mice at day 60 
pi (right). (D) The level of infectious virus was determined by plaque assay from serum 
samples over time (left) and liver, lung, and kidney tissues at day 60 (right). The dashed line 
represents the limit of detection. The data in panel A represent 9 mice from 3 independent 
experiments. All other panels represent 6 mice from 2 independent experiments.
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Figure 3. Direct LAG-3 signaling reduces the abundance of memory CD8+ T cells following acute 
viral infection
A dual adoptive transfer approach was used to directly compare the effect of LAG-3 
expression on CD8+ T cells following acute infection. (A) A mix containing 2×103 
Thy1.2+Ly5a+ WT P14 cells and 2×103 Thy1.2+Ly5a− LAG-3−/− P14 cells mice was 
adoptively transferred into Thy1.1+ B6.PL mice; 4 days later the mice were infected with 
LCMV-Armstrong. (B) An example of the gating strategy used to identify the WT and 
LAG-3−/− P14 cells. After gating on CD8+Thy1.2+ cells, the transferred cells were 
distinguished by their expression of Ly5a. (C) The frequency of each population of P14 cells 
among blood leukocytes in mice that were bled repeatedly following infection. (D) The total 
number of splenic WT and LAG-3−/− P14 cells at days 8 and 45 pi. (E–F) The frequency 
(left) and total number (right) of cytokine+ splenic WT and LAG-3−/− P14 cells at day 8 (E) 
and day 40 (F) as measured by ICS after ex vivo stimulation with GP33-41 peptide. The day 
8 data represent 5 mice from 2 independent experiments while the day 40 data represent 9 
mice from 3 independent experiments.
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Figure 4. Direct LAG-3 signaling inhibits the long-term maintenance of virus-specific CD8+ T 
cells during chronic infection
As illustrated in (A), 2×103 Thy1.1+Ly5a− WT P14 cells and 2×103 Thy1.1−Ly5a+ 
LAG-3−/− P14 cells were co-adoptively transferred into WT B6 mice (Thy1.1−Ly5a−); 4 
days later the mice were infected with LCMV-Clone 13 and T cell responses were measured 
at multiple times after infection. (B) An example of the gating strategy used to identify the 
transferred cells. After gating on CD8+ cells, the WT and LAG-3−/− P14 cells were 
distinguished by their expression of Thy1.1 and Ly5a, respectively. (C) The frequency of 
each population of P14 cells among blood leukocytes in mice that were bled repeatedly 
following infection. (D) The total number of splenic WT and LAG-3−/− P14 cells at day 56 
pi. (E) The frequency (left) and total number (right) of cytokine+ splenic WT and LAG-3−/− 
P14 cells at day 56, as measured by ICS following GP33-41 peptide stimulation. (F) 
Examples of surface staining for LAG-3, PD-1, 2B4, CD160, and KLRG-1 on splenic WT 
(thick line) and LAG-3−/− (thin line) P14 cells and naive CD8+ T cells (shaded) at day 56. 
These data represent 6 mice from 2 independent experiments.
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Figure 5. LAG-3 deficient CD8+ T cells outcompete WT CD8+ T cells
As illustrated in (A), 1×102, 2×103, or 4×104 Thy1.1+Ly5a− WT P14 cells with 1×102, 
2×103, or 4×104 Thy1.1−Ly5a+ LAG-3−/− (in B) or control WT (in C) P14 cells mice were 
co-transferred into WT B6 mice (Thy1.1−Ly5a−); 4 days later the mice were infected with 
LCMV-Armstrong and T cell responses were measured at day 16 post infection. (B) 
Examples of staining for Ly5a and Thy1.1 on gated CD8+ T cells (left) and the ratio of Ly5a
+:Thy1.1+ (LAG-3−/−:WT) P14 cells (right) in the spleen. (C) Examples of staining for 
Ly5a and Thy1.1 on gated CD8+ T cells (left) and the ratio of Ly5a+:Thy1.1+ (WT:WT) 
P14 cells (right) in the spleen. These data depict 3 mice from 1 experiment.
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Figure 6. WT CD8+ T cells establish lower levels of memory in the presence of endogenous 
LAG-3−/− CD8+ T cells
Cell transfer experiments were performed to determine whether LAG-3 expression by the 
host affects T cell responses to acute infection. (A) 2×104 Thy1.1+ WT P14 cells mice were 
adoptively transferred into Thy1.1− WT B6 or Thy1.1− LAG-3−/− mice; 4 days later the 
mice were infected with LCMV-Armstrong. (B) Examples of staining for the CD8+Thy1.1+ 
WT P14 cells in the spleens of WT or LAG-3−/− host mice at days 0 (uninfected), 8, and 40 
after infection; the numbers indicate the percentage of P14 cells among all spleen cells. (C) 
The total number of splenic WT P14 cells in either WT or LAG-3−/− host mice at days 8 and 
40 pi. (D–E) The frequency (left) and total number (right) of cytokine+ splenic WT P14 
cells in either WT or LAG-3−/− host mice at day 8 (D) and day 40 (E) as measured by ICS 
after ex vivo stimulation with GP33-41 peptide. These data represent 5-6 mice from 2 
independent experiments.
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Figure 7. LAG-3 expression has a minor impact on cell proliferation and apoptotic pathways
2×103 Thy1.1+Ly5a− WT P14 cells and 2×103 Thy1.1−Ly5a+ LAG-3−/− P14 cells mice 
were adoptively transferred into the same WT B6 mice (Thy1.1−Ly5a−); 4 days later the 
mice were infected with LCMV-Armstrong or Clone13. (A) The gMFI of Bcl-2 and Bim on 
WT and LAG-3−/− P14 cells at days 7 and 13 during Clone13 infection. (B) The Bim:Bcl-2 
ratio within each cell type at day 13 of Clone13 infection. (C and D) Splenocytes were 
isolated on days 7 or 13 and cultured in vitro for 6 hours. The frequency of AnnexinV+ (C) 
and activated Caspase 3 (D) P14 cells after the in vitro culture. (E) The frequency of Ki-67+ 
splenic WT and LAG-3−/− P14 cells at various times after infection. (F) Illustration showing 
the design of the in vivo proliferation assay. At 8 days post-infection, CD8+ T cells were 
isolated by MACS negative selection, CFSE labeled, and re-transferred to day 8 Clone13 
infected mice that had not previously received P14 cells; CFSE dilution was analyzed 3 days 
later. (G) Examples of CFSE dilution by WT and LAG3−/− P14 cells (left) and the total 
frequency of cells that had divided (right), with the lines indicating the paired analyses. The 
data in panels A and B represent 11 mice from 4 independent experiments. The data in panel 
C, D, and G represent 6 mice from 2 independent experiments. The data in panel E represent 
9 mice from 3 independent experiments.
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